These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15242682)

  • 21. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
    Kanakis I; Kousidou OCh; Karamanos NK
    In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
    Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
    Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of bisphosphonates in breast cancer.
    Coleman RE
    Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
    Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mechanism and treatment of cancer metastasis to bone].
    Yoneda T
    Clin Calcium; 2005 Jul; 15(7):29-37. PubMed ID: 15995293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are bisphosphonates the suitable anticancer drugs for the elderly?
    Santini D; Fratto ME; Galluzzo S; Vincenzi B; Tonini G
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):83-94. PubMed ID: 18692400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates in preclinical bone oncology.
    Clézardin P; Benzaïd I; Croucher PI
    Bone; 2011 Jul; 49(1):66-70. PubMed ID: 21145441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effects of bisphosphonates: promising preclinical evidence.
    Guise TA
    Cancer Treat Rev; 2008; 34 Suppl 1():S19-24. PubMed ID: 18486348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The application advances of bisphosphonates in bone metastasis].
    Liang P
    Zhongguo Gu Shang; 2008 Jun; 21(6):480-2. PubMed ID: 19108448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the horizon: can bisphosphonates prevent bone metastases?
    Coleman R
    Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
    Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
    Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effects of bisphosphonates: from the laboratory to the clinic.
    Berenson JR
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):233-40. PubMed ID: 21825999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.
    Clemons M; Dranitsaris G; Cole D; Gainford MC
    Oncologist; 2006 Mar; 11(3):227-33. PubMed ID: 16549806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of bone metastases with bisphosphonates].
    Gremaud M; Delouche D; Monnerat C
    Rev Med Suisse; 2006 Aug; 2(75):1861-6. PubMed ID: 16948423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
    Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
    Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.